CompletedNot Applicable

Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors

China100 participantsStarted 2020-03-24

Plain-language summary

Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Surgical resection is the main treatment option for colorectal cancer patients. Surgery may enhance or accelerate tumor recurrence and metastasis. Multiple factors in the tumor microenvironment play important roles in tumor recurrence and metastasis, and modulating the tumor microenvironment can inhibit disease progression. Lidocaine has been found to inhibit tumor growth in animal experiments.

Who can participate

Age range30 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * colorectal tumor patients Exclusion Criteria: * Weight \<45kg and \>100kg * Sensitivity or hypersensitivity to lidocaine * Second or third degree heart block * Severe heart failure (ejection fraction \< 20%) * History of active rhythm disorder * Acute severe liver and kidney injury * History of uncontrolled seizures * History of acute porphyria.

What they're measuring

the concentration of tumor micrometastasis markers were determined by ELISA

Timeframe: 3 days after surgery

Trial details

NCT IDNCT05484687

SponsorAffiliated Hospital of Nantong University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-30

View on ClinicalTrials.gov More Colorectal Tumors trials